once monthly glp-1 agonist Market Overview: Agonists and the Obesity Market | Blog GLP-1 Receptor Agonists: An Alternative

Reported protocols from research settings and case literature include: Subcutaneous self-injection at doses of 0.5-1 mg Loading phase protocols followed by maintenance dosing Typical research doses of 0.025 mg/kg in clinical studies No standardized reconstitution or storage protocols in unregulated use The self-administration model and lack of pharmaceutical-grade products create additional safety risks absent from the Melanotan-1 paradigm

These injections quickly address deficiency and support overall health

High protein intake at 1g per pound of bodyweight minimum

V.et al (2015)

Current medications: A list of other medications being taken, to ensure there are no interactions and that the GLP-1 therapy is the most appropriate option

Wound healing appears accelerated for those with active injuries